Can biochemical failure (ASTRO definition) be used as a surrogate endpoint for prostate cancer survival in phase III localized prostate cancer clinical trials? Analysis of RTOG protocol 92-02

Reviewer: Ryan Smith, MD
OncoLink
Ultima Vez Modificado: 31 de mayo del 2003

Translation for this article does not exist